{"id":1018,"date":"2021-05-26T10:42:56","date_gmt":"2021-05-26T10:42:56","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=1018"},"modified":"2021-05-26T10:44:21","modified_gmt":"2021-05-26T10:44:21","slug":"05-may-2021-lenzilumab-survival-was-improved-by-2-17-fold","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/05-may-2021-lenzilumab-survival-was-improved-by-2-17-fold\/","title":{"rendered":"(04 May 2021) Lenzilumab- survival was improved by 2.17-fold"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL<\/p>\n<p>https:\/\/www.medrxiv.org\/content\/10.1101\/2021.05.01.21256470v1<\/p>\n<p class=\"\">NCT04351152- Subjects received steroids (93.7%), remdesivir (72.4%), or both (69.1%). Lenzilumab improved the likelihood of SWOV by 54% in the mITT population (HR: 1.54; 95%CI: 1.02-2.31, p=0.041) and by 90% in the ITT population (HR: 1.90; 1.02-3.52, nominal p=0.043) compared to placebo. SWOV also relatively improved by 92% in subjects who received both corticosteroids and remdesivir (1.92; 1.20-3.07, nominal p=0.0067); by 2.96-fold in subjects with CRP&lt;150 mg\/L and age &lt;85 years (2.96; 1.63\u20135.37, nominal p=0.0003); and by 88% in subjects hospitalized \u22642 days prior to randomization (1.88; 1.13-3.12, nominal p=0.015). Survival was improved by 2.17-fold in subjects with CRP&lt;150 mg\/L and age &lt;85 years (2.17; 1.04-4.54, nominal p=0.040). Lenzilumab significantly improved SWOV in hospitalized, hypoxic subjects with COVID-19 pneumonia over and above treatment with remdesivir and\/or corticosteroids. Subjects with CRP&lt;150 mg\/L and age &lt;85 years demonstrated an improvement in survival and had the greatest benefit from lenzilumab.&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL https:\/\/www.medrxiv.org\/content\/10.1101\/2021.05.01.21256470v1 NCT04351152- Subjects received steroids (93.7%), remdesivir (72.4%), or both (69.1%). Lenzilumab improved the likelihood of SWOV by 54% in the&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/05-may-2021-lenzilumab-survival-was-improved-by-2-17-fold\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(04 May 2021) Lenzilumab- survival was improved by 2.17-fold&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,129],"tags":[],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/1018"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=1018"}],"version-history":[{"count":2,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/1018\/revisions"}],"predecessor-version":[{"id":1022,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/1018\/revisions\/1022"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=1018"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=1018"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=1018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}